Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016663 | 0.80 | RAB9A (0.40) | MAPK14GCGRRAB9ANPC1GRM2 | |
| SCHEMBL17016706 | 0.77 | MAPK14 (0.44) | MAPK14RAB9ANPC1TRPM8ALOX5 | |
| SCHEMBL21938179 | 0.71 | ACHE (0.46) | MAPK14GCGRRAB9ANPC1MEN1 | |
| SCHEMBL21363228 | 0.71 | ALOX15 (0.48) | MAPK14GCGRRAB9ANPC1ALOX5 | |
| SCHEMBL19067821 | 0.71 | ALOX15 (0.54) | MAPK14GCGRRAB9ANPC1ALOX5 | |
| SCHEMBL15577500 | 0.68 | SQOR (0.48) | MAPT | |
| SCHEMBL31353610 | 0.67 | GRM2 (0.45) | MAPK14GCGRRAB9ANPC1GRM2 | |
| SCHEMBL17016707 | 0.67 | MAP4K4 (0.44) | ALOX5MAP4K4 | |
| SCHEMBL31353619 | 0.66 | GRM2 (0.41) | MAPK14GCGRRAB9ANPC1GRM2 | |
| SCHEMBL1773298 | 0.66 | PDE3B (0.42) | MAPK14GCGRKDM4EMAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-9573938-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, P4HA1 | MAPK14 3982/4885GCGR 1490/4885RAB9A 3526/4885 |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, DHX15 | MAPK14 4176/4885GCGR 1381/4885RAB9A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.